Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
1-Zombie_Aqua_Viability_Dye_nowash_050713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • 1-Zombie_Aqua_Viability_Dye_nowash_050713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Quantity Check Availability Save
423101 100 tests 60,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423102 500 tests 228,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC, ICFC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References

(PubMed link indicates BioLegend citation)
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  2. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  3. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  4. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  5. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  6. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  7. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  8. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  9. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  10. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  11. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  12. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  13. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  14. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  15. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  16. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  17. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  18. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  19. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  20. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  21. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  22. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  23. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed
  24. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  25. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  26. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  27. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  28. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  29. Yuan C, et al. 2018. iScience. 11:13. PubMed
  30. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  31. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  32. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  33. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  34. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  35. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  36. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  37. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  38. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  39. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  40. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  41. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  42. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  43. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  44. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  45. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  46. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  47. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  48. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  49. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  50. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  51. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  52. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  53. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  54. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  55. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  56. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  57. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  58. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  59. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  60. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  61. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  62. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  63. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  64. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  65. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  66. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  67. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  68. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  69. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  70. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  71. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  72. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  73. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  74. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  75. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  76. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  77. Price P, et al. 2014. J Virol. 88:10840. PubMed
  78. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  79. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  80. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  81. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  82. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  83. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  84. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  85. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  86. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  87. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  88. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  89. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  90. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  91. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  92. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  93. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  94. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  95. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  96. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  97. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  98. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  99. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  100. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  101. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  102. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  103. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  104. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  105. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  106. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  107. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  108. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  109. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  110. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  111. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  112. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  113. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  114. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  115. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  116. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  117. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  118. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  119. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  120. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  121. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  122. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  123. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  124. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  125. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  126. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  127. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  128. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  129. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  130. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  131. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  132. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  133. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  134. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  135. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  136. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  137. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  138. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  139. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  140. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  141. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  142. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  143. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  144. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  145. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  146. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  147. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  148. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  149. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed
  150. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  151. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  152. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  153. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  154. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  155. Köchl R, et al. 2020. Elife. 9:00. PubMed
  156. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  157. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  158. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  159. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  160. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  161. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  162. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  163. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  164. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  165. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  166. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  167. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  168. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  169. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  170. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  171. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  172. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  173. Tasker C, et al. 2021. AAPS J. 23:26. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?
Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.
I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use your Zombie dyes for microscopy application?

Zombie dyes that have been tested for microscopy applications in-house will display data on the product webpage. It should be noted that Zombie may not work for dead cell discrimination in every microscopy application, as a complicated point will be to determine the level of Zombie signal that constitutes a dead cell. Another difficulty may be finding the proper plane for microscopy in order to observe the dead cells.

Why can't I fix my cells prior to using Zombie?

The fixation process can contort and alter the membrane of cells, effectively rendering them as dead. Since the ability of Zombie to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie and Annexin V to detect apoptotic cells?

Yes, Zombie can be used with Annexin V to discriminate live, apoptotic, and dead cells. Cells double positive for both Zombie and Annexin V are dead, while Zombie-dim/Annexin V-positive cells are apoptotic. Live cells will be Zombie-low and Annexin V-negative. The advantage to Zombie over PI and 7-AAD is that you can now fix and/or permeabilize the cells to stain for cell surface and intracellular antigens.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


Go To Top Version: 8    Revision Date: 01/27/2021

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account